NCT03315026
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary completion moved at least 11 months later.
See at-risk trials from Memorial Sloan Kettering Cancer Center
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 17 versions: 14 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Oct 2026 to Oct 2027
- Eligibility criteria expanded, about 27 words
- Notable Primary and study completion dates: Oct 2025 to Oct 2026v16
- Notable Primary and study completion dates: Oct 2024 to Oct 2025v15
- Notable Primary and study completion dates: Oct 2023 to Oct 2024v14
- Notable Primary and study completion dates: Oct 2021 to Oct 2023v11
Show 8 earlier versionsHide 8 earlier versions
- Notable Primary and study completion dates: Oct 2020 to Oct 2021v10
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Minor Enrollment target: 28 to 30v7
- Notable Primary and study completion dates: Oct 2019 to Oct 2020v6
- Notable Primary and study completion dates: Oct 2018 to Oct 2019v5
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria expanded, about 41 words
- Start date changed from estimate of Dec 2017 to Dec 14, 2017
- Site details revised
- Minor Start date: Nov 2017 to Dec 2017v3
- Minor Start date: Oct 2017 to Nov 2017v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
number of patients with improved symptoms
Timeframe: 30 days post ASCT
Arms and interventions
SiltuximabExperimental
Siltuximab 11mg/kg will be administered seven days before and 21 days after autologous stem cell infusion (+/-2 day).
Drugs: Siltuximab
Behavioral: The M.D. Anderson Symptom Inventory (MDASI)
Sites
1 site in 1 country
- Memorial Sloan Kettering Cancer CenterNew York, New York, United States